Importance of Serum SELDI-TOF-MS Analysis in the Diagnosis of Early Lung Cancer

  • Simsek, Cebrail (Chest Disease Department, Ataturk Chest Disease and Surgery Research and Education Hospital) ;
  • Sonmez, Ozlem (Chest Disease Department, Ataturk Chest Disease and Surgery Research and Education Hospital) ;
  • Yurdakul, Ahmet Selim (Chest Disease Department, Faculty of Medicine, Gazi University) ;
  • Ozmen, Fusun (Medical Oncology Department, Numune Education and Researh Hospital) ;
  • Zengin, Nurullah (Medical Oncology Department, Dr Abdurrahman Yurtaslan Education and Research Hospital) ;
  • Keyf, Atilla Isan (Chest Disease Department, Ataturk Chest Disease and Surgery Research and Education Hospital) ;
  • Kubilay, Dilek (Biochemistry Department, Dr Abdurrahman Yurtaslan Education and Research Hospital) ;
  • GUlbahar, Ozlem (Biochemistry Department, Faculty of Medicine, Gazi University) ;
  • Karatayli, Senem Ceren (Instıtute of Hepatology, Faculty of Medicine, Ankara University) ;
  • Bozdayi, Mithat (Instıtute of Hepatology, Faculty of Medicine, Ankara University) ;
  • Ozturk, Can (Chest Disease Department, Faculty of Medicine, Gazi University)
  • Published : 2013.03.30


Background: Different methods of diagnosis have been found to be inefficient in terms of screening and early diagnosis of lung cancer. Cancer cells produce proteins whose serum levels may be elevated during the early stages of cancer development. Therefore, those proteins may be recognized as potential cancer markers. The aim of this study was to differentiate healthy individuals and lung cancer cases by analyzing their serum protein profiles and evaluate the efficacy of this method in the early diagnosis of lung cancer. Materials and Methods: 170 patients with lung cancer, 53 under high risk of lung cancer, and 47 healthy people were included in our study. Proteomic analysis of the samples was performed with the SELDI-TOF-MS approach. Results: The most discriminatory peak of the high risk group was 8141. When tree classification analysis was performed between lung cancer and the healthy control group, 11547 was determined as the most discriminatory peak, with a sensitivity of 85.5%, a specificity of 89.4%, a positive predictive value (PPV) of 96.7% and a negative predictive value (NPV) of 62.7%. Conclusions: We determined three different protein peaks 11480, 11547 and 11679 were only present in the lung cancer group. The 8141 peak was found in the high-risk group, but not in the lung cancer and control groups. These peaks may prove to be markers of lung cancer which suggests that they may be used in the early diagnosis of lung cancer.


  1. Adam BL, Qu Y, Dawis JW, et al (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguish prostate cancer from the benign prostate hyperplasia anad healthy men. Cancer Res, 62, 3609-14.
  2. Alessandro R, Fontana S, Kohn E, De Leo G (2005). Proteomic strategies, and their application in cancer research. Tumori, 91, 447-55.
  3. Bellomi M, Rampinelli C, Funicelli L, et al (2006). Screening for lung cancer. Cancer Imaging, 31, 9-12.
  4. Clarke W, Zhang Z,Chan DW (2003). The application of clinical proteomics to cancer and other diseases. Clin Chem Lab Med, 41, 1562-70.
  5. Fontana RS, Sanderson DR, Taylor WF, et al (1984). Early lung cancer detection: results of the initial (prevelance) radiologic and cytologic screening in the Mayo clinic study. Am Rev Respir Dis, 130, 561-5.
  6. Gamez-Pozo A, Sanchez-Navarro I, Nistal M, et al (2009). MALDI profiling of human lung cancer subtypes. PLoS ONE, 4, 7731.
  7. Han K, Huang G, Gao C, et al (2008). Identification of lung cancer patients by serum protein profiling using surfaceenhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol, 31, 133-9.
  8. Hang ZQ, Zheng MF, Huang JH (2011). Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients. Zhonghua Zhong Liu Za Zhi, 33, 847-9.
  9. Hicks RJ, Lau E, Alam NZ, et al (2007). Imaging in the diagnosis and treatment of non-small cell lung cancer. Respirology, 12, 165-72.
  10. Huang LJ, Chen SX, Huang Y, et al (2006). Proteomic- based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer, 54, 87-94.
  11. Huber LA (2003). Is proteomics heading in the wrong direction? Nat Rev Mol Cell Biol, Xiao X, Wei XP, He DC (2003). Proteomic approaches to biomarker discovery in lung cancer by SELDI technology. Science in China series C. Life Sci, 46, 531-7.
  12. Jacot W, Lhermitte L, Dossat N, et al (2008). Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes. J Thorac Oncol, 3, 840-50.
  13. Jett JR (2002). Screening for lung cancer: no a taboo subject. J Clin Oncol, 20, 1959-61.
  14. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L (2002). Carcinoembryonic antigen, squamous cell carsinoma antigen, CYFRA 21-1, and neuro-spesific enolase in squamous cell lung cancer patients. Clin Chem, 48, 1931-7.
  15. Li J, Zhang Z, Rosenzweig J, et al (2002). Proteomics and bioinformatics approaches for identification of serum biomarkers to detec breast cancer. Clin Chem, 48, 1296-304.
  16. Lin X, Yang S, Du J, et al (2010). Detection of lung adenocarsinoma using magnetic beads based matrx-assisted laser desorption 7ionization time-of-flight mass spectrometry serum protein profiling. Chin Med J, 123, 34-9.
  17. Lopez E, Cho WCS (2012). Phosphoproteomics and Lung Cancer Research. Int J Mol Sci, 13, 12287-314.
  18. Melamed MR, Flehinger BJ, Zaman MB, et al (1984). Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New-York. Chest, 86, 44-53.
  19. Mountain CF (2000). The international system for staging lung cancer. Semin Surg Oncol, 18, 106.<106::AID-SSU4>3.0.CO;2-P
  20. Paradis V, Degos F, Dargere D, et al (2005). Identification of a new marker of hepatocellular carsinoma by serum protein profiling of patients with chronic liver disease. Hepatology, 41, 40-7.
  21. Parkin DM, Pisoni P, Ferlay J (1999). Global cancer statistics. CA Cancer J Clin, 49, 33-64.
  22. Pen J, Gygi SP (2001). Proteomics:the movie to mixtures. J Mass Spectrom, 36, 1083-91.
  23. Petricoin EF, Ardekani AM, Hitt BA, et al (2002). Use of prteomic patterns in serum to identify ovarian cancer. Lancet, 359, 572-77.
  24. Rosty C, Christa L, Kuzdzal S, et al (2002). Identification of hepatocarsinoma-intestine-pancreas/pancreatitis-associated protein as a biomarker for pancreatic ductal adenocarsinoma by protein biochip technology. Cancer Res, 62, 1868-75.
  25. Schneider J, Biterlich N, Velcovsky HG, et al (2002). Fuzzy logic- based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol, 7, 145-51.
  26. Schneider J, Velcovsky HG, Morr H, et al (2000). Comparison of the tumor markers tunor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res, 20, 5053-8.
  27. Spira A, Ettinger DS (2004). Multidisciplinary management of lung cancer. N Engl J Med, 350, 379-92.
  28. Sung HJ, Cho JY (2008). Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB reports, 41, 615-25.
  29. Wu CC, Chien KY, Tsang NM, et al (2005). Cancer cellsecreted proteomes as basis for searching potential tumor markers:nasopharyngeal carsinoma as a model. Proteomics, 5, 3173-82.
  30. Yang SY, Xiao XY, Zhang WG, et al (2005). Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer, 5, 1-7.
  31. Yildiz PB, Shyr Y, Rhman JSM, et al (2007). Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol, 2, 893-901.
  32. Zhong L, Peng X, Hidalgo GE, et al (2004). Identification of circulation antibodies to tumor-associated proteins for combined used as amarkers of non-small cell lung cancer. Proteomics, 4, 1216-25.

Cited by

  1. Alterations in the serum proteome profile during the development of ovarian cancer vol.45, pp.6, 2014,
  2. Serum protein profiles of patients with lung cancer of different histological types vol.12, pp.1, 2015,
  3. Comparative proteomics and global genome-wide expression data implicate role of ARMC8 in lung cancer vol.16, pp.9, 2015,